Dispositivos de inhalación para asma y EPOC: una revisión de la literatura

Inhalation devices for asthma and COPD: A review of the literature

Publicado 2019-08-15

Abrir | Descargar
PDF FLIP
Número
Vol. 31 Núm. 1 (2019)
Sección
Reportes de casos
Cómo citar
1.
Dispositivos de inhalación para asma y EPOC: una revisión de la literatura. rev. colomb. neumol. [Internet]. 2019 Aug. 15 [cited 2024 Nov. 15];31(1). Available from: https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/328
DOI

https://doi.org/10.30789/rcneumologia.v31.n1.2019.328
Dimensions
PlumX
Licencia

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Marian Rincon-Montaña
    Diego Rosselli
      Mostrar biografía de los autores

      Las investigaciones recientes se han concentrado en el desarrollo de nuevos dispositivos de inhalación. La innovación ha mejorado los inhaladores de dosis medida, polvo seco o res- piración controlada y los nebulizadores. El objetivo de este estudio fue realizar una revisión narrativa de la literatura acerca de los diferentes dispositivos de inhalación que se encuen- tran disponibles en el mercado y su asociación con los desenlaces para asma y EPOC. Las principales preocupaciones han sido facilitar la administración del medicamento al paciente favoreciendo la farmacocinética, seguridad, preferencia del paciente, cumplimiento de la medicación, calidad de vida y costos. La adherencia a la medicación tiene una asociación po- sitiva con la preferencia del paciente y la facilidad de uso del dispositivo que administra los medicamentos para el control de la enfermedad. Una buena adherencia a los medicamentos puede reducir los episodios de exacerbación, mejorar la calidad de vida y reducir los costos de las enfermedades respiratorias.

      Visitas del artículo 1770 | Visitas PDF 913

      Descargas

      Los datos de descarga todavía no están disponibles.
      1. Lasalvia P, Barahona-Correa JE, Romero-Alvernia DM, Gil- Tamayo S, Castaneda-Cardona C, Bayona JG, et al. Pen de- vices for insulin self-administration compared with needle and vial: Systematic review of the literature and meta-analy- sis. J Diabetes Sci Technol. 2016;10(4):959-66.
      2. Kukut Hatipoglu M, Hickey AJ, Garcia-Contreras L. Pharma- cokinetics and pharmacodynamics of high doses of inhaled dry powder drugs. Int J Pharm. 2018;549(1-2):306-16.
      3. Edsbacker S. New techniques for studying airway drug phar- macokinetics for asthma therapeutics. Expert Rev Clin Phar- macol. 2017;10(2):127-30.
      4. Arunthari V, Bruinsma RS, Lee AS, Johnson MM. A pro- spective, comparative trial of standard and breath-actuated nebulizer: efficacy, safety, and satisfaction. Respir Care. 2012;57(8):1242-7.
      5. Niven R. Prospects and challenges: inhalation delivery sys- tems. Ther Deliv. 2013;4(5):519-22.
      6. Pritchard JN, Giles RD. Opportunities in respiratory drug de- livery. Ther Deliv. 2014;5(12):1261-73.
      7. Edsbacker S, Johansson C-J. Airway selectivity: an update of pharmacokinetic factors affecting local and systemic dis- position of inhaled steroids. Basic Clin Pharmacol Toxicol. 2006;98(6):523-36.
      8. Olsson B, Borgstrom L, Lundback H, Svensson M. Validation of a general in vitro approach for prediction of total lung de- position in healthy adults for pharmaceutical inhalation prod- ucts. J Aerosol Med Pulm Drug Deliv. 2013;26(6):355-69.
      9. Snell NJ, Ganderton D. Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, U.K. on 17 April 1998. Respir Med. 1999;93(2):123-33.
      10. Pauwels R, Newman S, Borgstrom L. Airway deposition and airway effects of antiasthma drugs delivered from metered- dose inhalers. Eur Respir J. 1997;10(9):2127-38.
      11. Hubner M, Hochhaus G, Derendorf H. Comparative pharma- cology, bioavailability, pharmacokinetics, and pharmacody- namics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am. 2005;25(3):469-88.
      12. Skoner DP. Balancing safety and efficacy in pediatric asthma
      13. management. Pediatrics. 2002;109(2 Suppl):381-92.
      14. Ninane V, Vandevoorde J, Cataldo D, Derom E, Liistro G, Munghen E, et al. New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences. Respir Med. 2015;109(11):1430-8.
      15. Nakahara N, Wakamatsu A, Kempsford R, Allen A, Yamada M, Nohda S, et al. The safety, pharmacokinetics and phar- macodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. Int J Clin Pharmacol Ther. 2013;51(8):660-71.
      17. Salpeter SR. Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a sys- tematic review. Drugs Aging. 2004;21(6):405-14.
      18. Kelleher DL, Mehta RS, Jean-Francois BM, Preece AF, Blow- ers J, Crater GD, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS One. 2012;7(12):e50716.
      19. Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Mor- ris RM, Seltzer JM, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000;105(2):E23.
      20. Koya T, Hasegawa T, Takasawa J, Yoshimine F, Sakagami T, Hayashi M, et al. Influence of adherence to inhaled cortico- steroids and inhaler handling errors on asthma control in a japanese population. Intern Med. 2018;57(23):3357-63.
      21. Jahedi L, Downie SR, Saini B, Chan H-K, Bosnic-Anticevich
      22. S. Inhaler technique in asthma: How does it relate to patients’ preferences and attitudes toward their inhalers? J Aerosol Med Pulm Drug Deliv. 2017;30(1):42-52.
      23. Koehorst-ter Huurne K, Movig K, van der Valk P, van der Palen J, Brusse-Keizer M. The influence of type of inhalation device on adherence of COPD patients to inhaled medication. Expert Opin Drug Deliv. 2016;13(4):469-75.
      24. DePietro M, Gilbert I, Millette LA, Riebe M. Inhalation de- vice options for the management of chronic obstructive pul- monary disease. Postgrad Med. 2018;130(1):83-97.
      25. Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MCJM, Verhamme KMC. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45(2):396-407.
      26. Makela MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107(10):1481-90.
      27. Denyer J. Adherence monitoring in drug delivery. Expert Opin Drug Deliv. 2010;7(10):1127-31.
      28. Lopez-Vina A, Giner J, Molina J, Palicio J, Plaza J, Quintano JA, et al. Multidisciplinary consensus on the nonadherence to clinical management of inhaled therapy in Spanish asthma patients. Clin Ther. 2017;39(8):1730-1745.e1.
      29. Chan AHY, Stewart AW, Harrison J, Black PN, Mitchell EA, Foster JM. Electronic adherence monitoring device perfor- mance and patient acceptability: a randomized control trial. Expert Rev Med Devices. 2017;14(5):401-11.
      30. Aydemir Y. Assessment of the factors affecting the failure to use inhaler devices before and after training. Respir Med. 2015;109(4):451-8.
      31. Gregoriano C, Dieterle T, Breitenstein A-L, Durr S, Baum A, Maier S, et al. Use and inhalation technique of inhaled medi- cation in patients with asthma and COPD: data from a ran- domized controlled trial. Respir Res. 2018;19(1):237.
      32. Leiva-Fernandez F, Leiva-Fernandez J, Zubeldia-Santoyo F, Garcia-Ruiz A, Prados-Torres D, Barnestein-Fonseca P. Effi- cacy of two educational interventions about inhalation tech- niques in patients with chronic obstructive pulmonary disease (COPD). TECEPOC: study protocol for a partially random- ized controlled trial (preference trial). Trials. 2012;13:64.
      33. Plaza V, Lopez-Vina A, Entrenas LM, Fernandez-Rodriguez C, Melero C, Perez-Llano L, et al. Differences in adherence and non-adherence behaviour patterns to inhaler devices be- tween COPD and asthma patients. COPD. 2016;13(5):547-54.
      34. Miravitlles M, Soler-Cataluna JJ, Alcazar B, Viejo JL, Gar- cia-Rio F. Factors affecting the selection of an inhaler device for COPD and the ideal device for different patient profiles. Results of EPOCA Delphi consensus. Pulm Pharmacol Ther. 2018;48:97-103.
      35. Price D, Bosnic-Anticevich S, Briggs A, Chrystyn H, Rand C, Scheuch G, et al. Inhaler competence in asthma: common er- rors, barriers to use and recommended solutions. Respir Med. 2013;107(1):37-46.
      36. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martuc- ci P, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930-8.
      37. Price D, Keininger DL, Viswanad B, Gasser M, Walda S, Gutzwiller FS. Factors associated with appropriate inhaler use in patients with COPD - lessons from the REAL survey. Int J Chron Obstruct Pulmon Dis. 2018;13:695-702.
      38. Emeryk A, Pirozynski M, Emeryk-Maksymiuk J. Dry powder inhalers - between the doctor and the patient. Adv Respir Med. 2018;86(1):44-52.
      39. Takemura M, Mitsui K, Itotani R, Ishitoko M, Suzuki S, Mat- sumoto M, et al. Relationships between repeated instruction on inhalation therapy, medication adherence, and health status in chronic obstructive pulmonary disease. Int J Chron Ob- struct Pulmon Dis. 2011;6:97-104.
      40. Molimard M, Colthorpe P. Inhaler devices for chronic ob- structive pulmonary disease: insights from patients and healthcare practitioners. J Aerosol Med Pulm Drug Deliv. 2015;28(3):219-28.
      41. Ding B, Small M, Scheffel G, Holmgren U. Maintenance inhaler preference, attribute importance, and satisfaction in prescribing physicians and patients with asthma, COPD, or asthma-COPD overlap syndrome consulting for routine care. Int J Chron Obstruct Pulmon Dis. 2018;13:927-36.
      42. Hawken N, Torvinen S, Neine M-E, Amri I, Toumi M, Aballea S, et al. Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment. BMC Pulm Med. 2017;17(1):99.
      43. Barrons R, Pegram A, Borries A. Inhaler device selec- tion: special considerations in elderly patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2011;68(13):1221-32.
      45. Dhand R, Cavanaugh T, Skolnik N. Considerations for Opti- mal Inhaler Device Selection in Chronic Obstructive Pulmo- nary Disease. Cleve Clin J Med. 2018;85(2 Suppl 1):S19-27.
      46. Goris S, Tasci S, Elmali F. The effects of training on inhaler technique and quality of life in patients with COPD. J Aerosol Med Pulm Drug Deliv. 2013;26(6):336-44.
      47. Boonsawat W, Thompson PJ, Zaeoui U, Samosorn C, Acar G, Faruqi R, et al. Survey of asthma management in Thailand
      48. - the asthma insight and management study. Asian Pacific J
      49. Allergy Immunol. 2015;33(1):14-20.
      50. Chogtu B, Holla S, Magazine R, Kamath A. Evaluation of re- lationship of inhaler technique with asthma control and qual- ity of life. Indian J Pharmacol. 2017;49(1):110-5.
      51. Juniper EF, Wisniewski ME, Cox FM, Emmett AH, Nielsen KE, O’Byrne PM. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J. 2004;23(2):287-91.
      52. Osman IM, Godden DJ, Friend JA, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chron- ic obstructive pulmonary disease. Thorax. 1997;52(1):67-71.
      53. Dudvarski Ilic A, Zugic V, Zvezdin B, Kopitovic I, Cekerevac I, Cupurdija V, et al. Influence of inhaler technique on asthma and COPD control: a multicenter experience. Int J Chron Ob- struct Pulmon Dis. 2016;11:2509-17.
      54. Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhin- gran P, Stanford R, et al. Cost-effectiveness of fluticasone pro- pionate/salmeterol (500/50 microg) in the treatment of COPD. Respir Med. 2009;103(1):12-21.
      55. Nair A, McKinlay L, Williamson P, Short P, Burns P, Lipworth BJ. Comparative lung bioavailability of fluticasone/salmeter- ol via a breath-actuated spacer and conventional plastic spac- ers. Eur J Clin Pharmacol. 2011;67(4):355-63.
      56. Nair A, Clearie K, Menzies D, Meldrum K, McFarlane L, Lipworth BJ. A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluti- casone/salmeterol in combination. Pulm Pharmacol Ther. 2009;22(4):305-10.
      57. Janssens W, VandenBrande P, Hardeman E, De Langhe E, Philps T, Troosters T, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78-83.
      58. Lavorini F. The challenge of delivering therapeutic aerosols to asthma patients. ISRN Allergy. 2013;2013:102418.
      59. Balamurugan S, Apte K, Singh B, Deb A, Deshmukh C, Modi K, et al. Device-handling study of a novel breath-actuated inhaler, Synchrobreathe®, versus a pMDI. Respir Med. 2019;In press.
      60. Perriello EA, Sobieraj DM. The Respimat soft mist in- haler, a novel inhaled drug delivery device. Conn Med. 2016;80(6):359-64.
      61. Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int J Pharm. 2004;283(1-2):1-9.
      62. Hira D, Koide H, Nakamura S, Okada T, Ishizeki K, Yama- guchi M, et al. Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using in- spiratory flow meter for multi inhalation devices. PLoS One. 2018;13(2):e0193082.
      63. Kassner F, Hodder R, Bateman ED. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat soft mist inhaler in patients with asthma and chronic obstructive pulmonary disease. Drugs. 2004;64(15):1671-82.
      64. Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat soft mist inhaler. Int J Chron Obstruct Pulmon Dis. 2009;4:381-90.
      65. Jones TL, Neville DM, Chauhan AJ. The Ellipta® in asthma and chronic obstructive pulmonary disease: device character- istics and patient acceptability. Ther Deliv. 2018;9(3):169-76.
      66. van der Palen J, Thomas M, Chrystyn H, Sharma RK, van der Valk PD, Goosens M, et al. A randomised open-label cross- over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: compari- son of ELLIPTA with other inhaler devices. NPJ Prim care Respir Med. 2016;26:16079.
      67. Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Bro- eders M, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102(4):593-604.
      68. Grant AC, Walker R, Hamilton M, Garrill K. The ELLIPTA® dry powder inhaler: design, functionality, in vitro dosing per- formance and critical task compliance by patients and care- givers. J Aerosol Med Pulm Drug Deliv. 2015;28(6):474-85.
      69. Azouz W, Chrystyn H. Clarifying the dilemmas about inhala- tion techniques for dry powder inhalers: integrating science with clinical practice. Prim Care Respir J. 2012;21(2):208-13.
      70. Campbell LM, Anderson TJ, Parashchak MR, Burke CM,
      71. Watson SA, Turbitt ML. A comparison of the efficacy of
      73. long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group. Respir Med. 1999;93(4):236-44.
      74. Oliveira MVC de, Pizzichini E, da Costa CH, Fritscher CC, Vianna EO, Teixeira PJZ, et al. Evaluation of the preference, satisfaction and correct use of Breezhaler® and Respimat® inhalers in patients with chronic obstructive pulmonary dis- ease - INHALATOR study. Respir Med. 2018;144:61-7.
      75. Florez-Tanus A, Parra D, Zakzuk J, Caraballo L, Alvis-Guz- man N. Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis. World Allergy Organ J. 2018;11(1):26.
      76. Pérez N, Murillo R, Pinzón C, Hernández G. Costos de la at- ención médica del cáncer de pulmón, la EPOC y el IAM atri- buibles al consumo de tabaco en Colombia (proyecto multicén- trico de la OPS). Rev Colomb Cancerol. 2007;11(4):241-9.
      77. Forster R, Ratcliffe A, Lewis M, Crossley A, Bastida JL, Dun- lop WCN. Cost-utility analysis of an intervention designed to reduce the critical handling error of insufficient inspiratory ef- fort. Eur J Health Econ. 2018;19(9):1303-18.
      78. Lewis A, Torvinen S, Dekhuijzen PNR, Chrystyn H, Watson AT, Blackney M, et al. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries. BMC Health Serv Res. 2016;16:251.
      79. Fernández-Avila D, Rojas M, Rosselli D. El método Delphi en la investigación en reumatología: ¿lo estamos haciendo bien? Rev Colomb Reumatol. 2019;in press.
      80. Ninane V, Brusselle GG, Louis R, Dupont L, Liistro G, De Backer W, et al. Usage of inhalation devices in asthma and chronic obstructive pulmonary disease: a Delphi consensus statement. Expert Opin Drug Deliv. 2014;11(3):313-23.

      Información

      Historia de la revista

      Palabras clave

      Directorios e indexadores

       

      Perfil de Google Scholar

      Más leídos en los últimos 30 días

      Número actual

      Código QR

      Sistema OJS 3.4.0.7 - Metabiblioteca |